Physician profile
Sireen Gopal
NPI 1720183551
$8,131.56
in general payments reported to CMS, 2019-2025
28 companies · $275 in 2025
The $275 reported for 2025 was more than what a typical provider received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,006 · 2020: $1,410 · 2021: $1,231 · 2022: $1,243 · 2023: $1,291 · 2024: $675 · 2025: $275.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,241.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,240.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $4,698.35 | 2019-2025 | Wavewriter Alpha Prime 16, General - Pain Management |
| Scilex Pharmaceuticals INC. | $546.37 | 2021-2025 | Ztlido |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $359.97 | 2019-2020 | |
| Horizon Therapeutics Plc | $319.15 | 2019-2022 | |
| Abbott Laboratories | $274.63 | 2019-2021 | |
| Medtronic, INC. | $201.29 | 2021 | |
| Amgen INC. | $181.97 | 2019-2020 | |
| Nevro Corp. | $171.94 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $157.38 | 2023 | Seglentis |
| Allergan, INC. | $150.00 | 2019 | |
| Pfizer INC. | $135.52 | 2019-2021 | |
| Medtronic USA, INC. | $131.06 | 2019-2020 | |
| Azurity Pharmaceuticals, INC. | $111.58 | 2023-2024 | Horizant, Horizant |
| Si-Bone, INC. | $100.36 | 2019-2021 | |
| Arbor Pharmaceuticals, INC. | $95.06 | 2019-2022 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Grt US Holding, INC. | $84.65 | 2021 | |
| Collegium Pharmaceutical, INC. | $71.86 | 2019-2024 | Belbuca |
| Bioventus LLC | $57.35 | 2022 | |
| Daiichi Sankyo INC. | $43.72 | 2019 | |
| Redhill Biopharma INC. | $42.17 | 2020-2021 | |
| Fidia Pharma USA INC. | $40.96 | 2019-2021 | |
| Shionogi INC | $31.55 | 2019 | |
| Spineology INC. | $30.58 | 2020 | |
| Astrazeneca Pharmaceuticals LP | $28.06 | 2019-2020 | |
| Almatica Pharma LLC | $22.76 | 2021 | |
| Vertical Pharmaceuticals, LLC | $17.02 | 2019 | |
| Idorsia Pharmaceuticals US INC | $14.77 | 2023 | Quviviq |
| Depuy Synthes Sales INC. | $11.48 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sireen Gopal listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.